Gain Therapeutics, Inc.
GANX
Rank in Stocks
#22916
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of... Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed proteins. Subsequently, Gain Therapeutics identifies proprietary small molecules designed to bind to these locations, thereby restoring correct protein conformation and alleviating the disease. Their current development pipeline includes several structurally targeted allosteric regulator candidates aimed at combating a range of diseases, such as Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1. Established in 2017, the company is headquartered in Bethesda, Maryland.
Share Price
$1.08
Last synced: 2026-11-12
Market Cap
$47.27M
Change (1 day)
-2.70%
Change (1 year)
-61.84%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Gain Therapeutics, Inc. (GANX)
Category
Healthcare
Operating Margin for Gain Therapeutics, Inc. (GANX)
Operating Margin as of November 2026 TTM: 0.00%
According to Gain Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Gain Therapeutics, Inc. from 2018 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | -100.00% |
| 2023 | -40,328.26% | 200.90% |
| 2022 | -13,402.48% | 29.82% |
| 2021 | -10,323.59% | -14.31% |
| 2020 | -12,047.54% | 136.93% |
| 2019 | -5,084.89% | 1.91% |
| 2018 | -4,989.66% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| -195.39% | - |
US
|
|
| 33.87% | - |
US
|
|
| -116.04% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Gain Therapeutics, Inc.'s operating margin
What was Gain Therapeutics, Inc.'s operating margin in 2025?
In 2025, Gain Therapeutics, Inc.'s operating margin was 0.00%, compared with 0.00% in 2024.
How has Gain Therapeutics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Gain Therapeutics, Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2023 (-40,328.26%).
How does Gain Therapeutics, Inc.'s operating margin compare with similar companies?
Gain Therapeutics, Inc.'s operating margin (0.00%) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.